Boan Biotech Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 690

Employees

  • Stock Symbol
  • 06955

Stock Symbol

  • Share Price
  • $0.40
  • (As of Friday Closing)

Boan Biotech General Information

Description

Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 39, Science and Technology Avenue
  • High-tech Zone
  • Yantai, Shandong
  • China
+86 0535
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • No. 39, Science and Technology Avenue
  • High-tech Zone
  • Yantai, Shandong
  • China
+86 0535

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Boan Biotech Stock Performance

As of 20-Nov-2026, Boan Biotech’s stock price is $0.40. Its current market cap is $243M with 614M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.40 $0.40 $0.31 - $1.44 $243M 614M 1.93M -$0.02

Boan Biotech Financials Summary

As of 30-Jun-2026, Boan Biotech has a trailing 12-month revenue of $89.2M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 322,216 699,673 710,521 1,017,500
Revenue 89,235 109,135 101,222 87,370
EBITDA 5,093 17,956 24,854 (3,347)
Net Income (13,774) 993 10,200 (16,873)
Total Assets 597,760 589,655 390,582 327,764
Total Debt 124,161 111,949 93,908 57,262
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Boan Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Boan Biotech‘s full profile, request access.

Request a free trial

Boan Biotech Patents

Boan Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026189212-A1 Anti-gd2 antibody and antibody-drug conjugate thereof Pending 12-Mar-2025
WO-2026171129-A1 Bispecific antibody targeting egfr and b7h3, and antibody-drug conjugate thereof Pending 17-Feb-2025
WO-2026039940-A1 Enhanced dll3-protein-targeting chimeric antigen receptor and mutant, and use thereof Pending 19-Aug-2024
EP-4803098-A1 Gipr blocking type antibody and antibody conjugate thereof Pending 31-Oct-2023
WO-2025092705-A1 Gipr blocking type antibody and antibody conjugate thereof Inactive 31-Oct-2023 C07K16/2869
To view Boan Biotech’s complete patent history, request access »

Boan Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Boan Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Boan Biotech‘s full profile, request access.

Request a free trial

Boan Biotech ESG

Risk Overview

Risk Rating

Updated April, 30, 2024

32.83 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,111

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view Boan Biotech’s complete esg history, request access »

Boan Biotech FAQs

  • When was Boan Biotech founded?

    Boan Biotech was founded in 2013.

  • Where is Boan Biotech headquartered?

    Boan Biotech is headquartered in Yantai, China.

  • What is the size of Boan Biotech?

    Boan Biotech has 690 total employees.

  • What industry is Boan Biotech in?

    Boan Biotech’s primary industry is Drug Discovery.

  • Is Boan Biotech a private or public company?

    Boan Biotech is a Public company.

  • What is Boan Biotech’s stock symbol?

    The ticker symbol for Boan Biotech is 06955.

  • What is the current stock price of Boan Biotech?

    As of 20-Nov-2026 the stock price of Boan Biotech is $0.40.

  • What is the current market cap of Boan Biotech?

    The current market capitalization of Boan Biotech is $243M.

  • What is Boan Biotech’s current revenue?

    The trailing twelve month revenue for Boan Biotech is $89.2M.

  • What is Boan Biotech’s annual earnings per share (EPS)?

    Boan Biotech’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process